FRR Shares (Makes you Realise)

Equity

Home/ Are You A Trader/ Market Info/ Company Profile/ Smart Quotes

COMPANY PROFILE

EMCURE PHARMACEUTICALS LTD.

NSE : EMCUREBSE : 544210ISIN CODE : INE168P01015Industry : Pharmaceuticals & DrugsHouse : Private

BSE1288.65117.15 (+10 %)

PREV CLOSE (Rs.) 1171.50

OPEN PRICE (Rs.) 1202.10

BID PRICE (QTY) 1288.65 (36561)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 27784

TODAY'S LOW / HIGH (Rs.)1202.10 1288.65

52 WK LOW / HIGH (Rs.)890 1577.5

NSE1284.40116.7 (+9.99 %)

PREV CLOSE( Rs. ) 1167.70

OPEN PRICE (Rs.) 1205.00

BID PRICE (QTY) 1284.40 (191360)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 330463

TODAY'S LOW / HIGH(Rs.) 1201.00 1284.40

52 WK LOW / HIGH (Rs.)889 1580

More From Company Profile

Smart Quotes

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Trade Value (Rs. in Lacs)

358.04

Dividend Yield(%)

0.23

TTM EPS (Rs.)

16.74

P/E Ratio

77.00

Book Value (Rs.)

159.61

Face Value (Rs.)

MCap (Rs. in Mn)

244177.72

Price/Earning (TTM)

45.04

Price/Sales (TTM)

5.57

Price/Book (MRQ)

8.07

PAT Margin (%)

4.60

ROCE (%)

10.70

Incorporation Year : 16-04 1981

Management Info :

Berjis Minoo Desai - Chairman Satish Ramanlal Mehta - Managing Director

Registered Office :

Address : Plot No. P-1 & P-2,I T - B T Park, Phase- I I,M I D C, Hinjawadi,
Pune,
Maharashtra-411057

Phone : 020-3507003 / 35070000

Email : investors@emcure.com

Website : www.emcure.com

Registrars Details :

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

23May Emcure Pharmaceuticals touches the roo
Emcure Pharmaceuticals is locked its upper circuit at Rs. 1288.65, up by..

23May Emcure Pharmaceuticals gets nod to inc
Emcure Pharmaceuticals has received approval for incorporation of a whol..

22May Emcure Pharmaceuticals informs about c
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

Financials

	QTR Mar 25	ANNUAL 25
Net Profit	1395.57	3171.28
Gross Profit	1860.52	4277.1
Operating Profit	2670.33	7656.44
Net Sales	12781.88	43819.24

Rs. in Millions

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE)

6309.60 (0.80%)

M.Cap (Rs. in Cr)14531.40

SMS Lifesciences (BSE)

1366.60 (2.14%)

M.Cap (Rs. in Cr)413.16

Medplus Health Servi (BSE)

914.10 (3.21%)

M.Cap (Rs. in Cr)10884.36

Innova Captab (BSE)

895.20 (3.25%)

M.Cap (Rs. in Cr)5095.02

Shareholding Pattern

	PROMOTERS	77.92%
	NON-INSTITUTION	15.57%
	MUTUAL FUNDS/UTI	2.73%
	FI/BANKS/INSURANCE	0.19%
	GOVERNMENT	0%
	FII	0%

Mf Holding

Scheme Name

Hold(%)

Bajaj Finserv Healt...

2.48

Aditya Birla SL Pha...

2.12

DSP Healthcare Fund...

1.22

Edelweiss Recently ...

1.20

UTI Healthcare Fund...

1.18

ITI Pharma & Health...

1.17

Aditya Birla SL Bal...

1.04

Attention Investors

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month, Issued in the interest of Investors.

Risk Disclosure on Derivatives | Smart ODR | Mandatory Display | KYC Validation Links

BSE / NSE SEBI Registration No. INZ000279232, Depository Participant SEBI Registration No. – IN DP CDSL 132-2015

Mutual funds - ARN No. 81648 , Investment Adviser SEBI Registration No. : INA000008668.

CLOSE X

Risk Disclosures On Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22

EMCURE PHARMACEUTICALS LTD.

Smart Quotes

Attention Investors

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :

Filing complaints on SCORESEasy & quick

Risk Disclosures On Derivatives